Moreover, a plethora of genomic alterations have been identified, such as HER2, FGFR2, EGFR, PI3K, mTOR, and MET, which provided good identification of GC patients who derive therapeutic benefit from ACT (20). This evidence concerns the gene FGFR2 and gastric cancer.